OCUL NASDAQ
Ocular Therapeutix, Inc.
1W: -13.5%
1M: -14.9%
3M: +5.7%
YTD: -30.5%
1Y: +8.2%
3Y: +31.7%
5Y: -44.5%
$8.23
+0.01 (+0.12%)
Weekly Expected Move ±4.8%
$8
$9
$9
$10
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (48)
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Ocular Therapeutix outlines SOL-R top line data in Q1 2027 while advancing AXPAXLI NDA plan
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix misses Q1 street views
Earnings Scheduled For May 5, 2026
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix Q1 2026 Earnings Preview
William Blair updates conviction stock list
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Ocular Therapeutix, Inc. $OCUL Stock Position Lessened by Deltec Asset Management LLC
Courier Capital LLC Decreases Stake in Ocular Therapeutix, Inc. $OCUL
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 7.2% – Here’s What Happened
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts
EyePoint sues Ocular over claims related to lead asset
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
Ocular Therapeutix, Inc. $OCUL Shares Purchased by Avoro Capital Advisors LLC
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Grows By 27.8%
Citigroup Inc. Buys 573,504 Shares of Ocular Therapeutix, Inc. $OCUL
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts
Ocular Therapeutix Shares Jump After AXPAXLI Hits SOL-1 Phase 3 Endpoint in Wet AMD
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 9.5% – Time to Buy?
Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Stock Traders Purchase Large Volume of Put Options on Ocular Therapeutix (NASDAQ:OCUL)
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength?
Biotech outperformance expected to continue in 2026, Baird analysts say
Head to Head Comparison: Ocular Therapeutix (NASDAQ:OCUL) & Sonoma Pharmaceuticals (NASDAQ:SNOA)
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts
Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet